From: oncnursingnews.com Patients with HER2-negative metastatic breast cancer may soon have a more convenient treatment option, as the phase 3 OPTIMAL trial (NCT03315364) confirms that DHP107, a novel oral paclitaxel formulation, is non-inferior to traditional intravenous (IV) paclitaxel. From January 2018 to December 2023, researchers at 51 sites across South Korea, China, and Europe evaluated 549 patients to determine if …
Long-Term Physical Decline After Breast Cancer Therapy
By: Maurie Markman, MD From: medscape.com Clearly, it is well recognized, well established, and not controversial that chemotherapy and hormone therapy improve survival in breast cancer. Whether you’re looking at this in the metastatic setting in advanced disease or in the adjuvant setting, studies over multiple decades have clearly demonstrated improved survival when, of course, the therapy is given based …
Writing About Your Breast Cancer
View PostNew NCCN Guidelines Call for AI-Based Mammogram Risk Assessment at 35
By Sadia H. Zapp From: bcrf.org New guidelines from the National Comprehensive Cancer Network® champion artificial intelligence in breast cancer screening Key Takeaways New NCCN guidelines introduce AI-based risk assessment using mammograms to predict a woman’s 5-year breast cancer risk Risk assessment via mammogram to begin at age 35, marking a major shift toward earlier identification and intervention A ≥1.7% …
Breast Cancer Mortality Drops in US, but Pockets of Racial Disparities Remain
By: Mary Ellen Schneider From: cancertherapyadvisor.com Breast cancer mortality is down overall, but investigators saw increasing rates for Latin, American Indian/Alaska Native, and Asian women in a significant proportion of counties. The mortality rate for breast cancer has declined in the US over the past 20 years, but some counties have seen mortality increases for women who are American Indian …
Radiation may spark tissue changes that help triple-negative breast cancer return
By: Vanderbilt University From; medicalxpress.com While radiation therapy is an effective tool to destroy cancer cells, a new study from Vanderbilt researchers suggests that in an aggressive form of breast cancer, it may also trigger a protective cellular response that may explain why our current therapies fail some patients. The research was led by Marjan Rafat, assistant professor of chemical …
However, as it is written …
“However, as it is written: “What no eye has seen, what no ear has heard, and what no human mind has conceived”— the things God has prepared for those who love him.” 1 Corinthians 2:9 Barbara JacobyBarbara Jacoby is an award winning blogger that has contributed her writings to multiple online publications that have touched readers worldwide. LetLifeHappen.com
Better Survival, Cardiometabolic Outcomes in Breast Cancer Patients With Sufficient Vitamin D Levels
Women with breast cancer who have sufficient vitamin D levels have improved survival outcomes compared to those with vitamin D deficiency, according to research published in the Journal of the National Comprehensive Cancer Network. Patients with sufficient levels of vitamin D also have a lower incidence of cardiometabolic risk factors than those without sufficient levels, study researchers reported. In this …
Left-Side Breast Cancer EBRT Linked to Minimal Long-Term Cardiovascular Risk
By: Mary Ellen Schneider From: cancertherapyadvisor.com External beam radiation therapy (EBRT) for left-sided breast cancer has limited long-term cardiovascular risks, according to results published in JAMA Network Open. The findings suggest that contemporary photon-based EBRT techniques that reduce mean radiation dose to the heart have resulted in lower cardiovascular risks than those historically associated with left-side breast cancer radiation treatment, …
Advancing Immunotherapy in Metastatic Cancers: Identifying Mechanisms, Targeting Sanctuaries
By: Jasenka Piljac Zegarac, PhD From: ascopubs.org Key Points: As the use of immunotherapy for the treatment of metastatic cancers advances, challenges remain in understanding the mechanisms of metastasis and why certain tumors spread to specific distant organs. Oncologists still treat metastatic disease based on the original tumor site, and most treatment guidelines often do not consider the specific site …